ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
2期
提前终止
NCT03445000
| 适应症 | Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent |
|---|
| 分期 | 2期 |
|---|
| 申办方 | ETOP IBCSG Partners Foundation |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 14 人 |
|---|
| 干预（药物） | Alectinib |
|---|
| 开始日期 | 2018年11月6日 |
|---|
| 完成日期 | 2021年3月31日 |
|---|
| 结果公布日 | 2025年3月26日 |
|---|
摘要
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.
Best Overall Response (BOR)
Evaluated from enrollment through study completion, up to a maximum of 28 months. · Participants
| Trial Treatment | 0 Participants |
|---|
| Trial Treatment | 0 Participants |
|---|
| Trial Treatment | 9 Participants |
|---|
| Trial Treatment | 1 Participants |
|---|
| Trial Treatment | 2 Participants |
|---|
| Trial Treatment | 1 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。